Sectoral Derivative Snapshot
SBI Securities
Retail Research
Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
---|---|---|---|---|---|---|---|---|---|---|---|
10 Sep 2025 | Nifty 50 |
SBI Securities
|
25169.50 |
Daily Note
|
|||||||
10 Sep 2025 | Nifty 50 |
SBI Securities
|
25169.50 |
Daily Note
|
|||||||
10 Sep 2025 | Nifty 50 |
invest4Edu
|
25169.50 |
Daily Note
|
|||||||
10 Sep 2025 | Bank Nifty |
SBI Securities
|
55509.75 |
Daily Note
|
|||||||
10 Sep 2025 | World Economy and Markets |
Axis Direct
|
Daily Note
|
||||||||
10 Sep 2025 | Bank Nifty |
SBI Securities
|
55509.75 |
Daily Note
|
|||||||
10 Sep 2025 | Brokerage Research Reports |
Geojit BNP Paribas
|
Sell
|
DIVI' S LAB
Geojit BNP Paribas
The company's outlook remains positive due to growth drivers such as increased traction from global innovators, a healthy pipeline of RFPs, expansion of scientific and technological capabilities, and steady growth in the nutraceutical business. Management highlighted persistent pricing pressures in generics and higher cost escalation compared to custom synthesis, weighing on margins. Regulatory delays of 12-24 months for peptides, contrast media, and Kakinada approvals restricted near term revenue conversion. Divi's also faces the risk of losing business related to...
|
|||||||
10 Sep 2025 | Market Movement |
Ventura
|
Daily Note
|
||||||||
09 Sep 2025 | Nifty 50 |
invest4Edu
|
25169.50 |
Daily Note
|
|||||||
09 Sep 2025 | Nifty 50 |
Deven Choksey
|
25169.50 |
Daily Note
|
|||||||
more
loading
|